Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00032903
Status:
COMPLETED
Last Update Posted:
2009-06-03
First Post:
2002-04-05
Brief Title:
This is an Early Study to Investigate the Effect of Gimatecan in Adults With Malignant Glioma
Sponsor:
Sigma-Tau Research Inc
Organization:
Sigma-Tau Research Inc
Study Overview
Official Title:
Oral ST1481 in Adults With Malignant Glioma a Phase I-II Clinical Trial
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Gimatecan is Sigma-Tau Researchs new potent oral Topoisomerase I inhibitor Drugs in this class play a crucial role in destroying DNA replication in tumors We are conducting this study to determine the Maximum Tolerated Dose of our compound In addition we plan to assess the drugs ability to affect the evolution of malignant gliomas when given as a capsule rather than by intravenous injection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None